Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2002

View Archived Issues

NNC-45-0781, a promising candidate for postmenopausal osteoporosis

Antitumor effects demonstrated for rapamycin at immunosuppressive doses

Influenza vaccination reduces risk of brain infarction according to French researchers

Seattle Genetics and Genencor jointly develop ADEPT products including SGN-17/19

FDA approves BioPort anthrax vaccine license supplements

Preclinical evidence for efficacy of celecoxib in inflammatory bowel disease

Forbes Medi-Tech initiates phase I trial of cholesterol-lowering pharmaceutical

AltaRex offers further analysis of OvaRex results

Corixa reports progress in 2001

Malarex: a natural alternative in the fight against malaria

Chiron and Global Alliance for TB Drug Development collaborate on PA-824

Gleevec approved for gastrointestinal stromal tumors

National Institute on Aging studies genetic traits in Sardinians

Oxigene highlights product developments in fourth quarter 2001

First approval obtained for antihypertensive combination developed in Spain

Clinical testing of candidate HIV vaccine developed at GSK commences in U.S.

Tricyclic compounds that inhibit MRP-1 are useful as oncolytics

Radiolabeled nucleoside compounds for use as cancer imaging and therapeutic agents

Corixa designs isoleucine-containing peptide prodrugs of antitumor agents

Quinazoline derivatives that act as NPY antagonists for eating disorders, etc.

Preparation and use of pipecolic acid derivatives with MMP-inhibitory activity

Aromatic alphavbeta3 and/or alphavbeta5 integrin receptor antagonists disclosed by Pharmacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...